Statement of Changes in Beneficial Ownership (4)
October 31 2013 - 5:13PM
Edgar (US Regulatory)
FORM 4
[
X
]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
DAHLBERG KATHLEEN
|
2. Issuer Name
and
Ticker or Trading Symbol
THERAGENICS CORP
[
TGX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__
X
__ Director
_____ 10% Owner
_____ Officer (give title below)
_____ Other (specify below)
|
(Last)
(First)
(Middle)
96 SOUTH GEORGE STREET, SUITE 500
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
10/29/2013
|
(Street)
YORK, PA 17401
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock
|
10/29/2013
|
|
D
|
|
90000
(1)
|
D
|
$2.20
(1)
|
0
|
D
|
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Stock Option (Right to Buy)
|
$1.02
|
10/29/2013
|
|
D
|
|
|
5000
|
(2)
|
5/14/2019
|
Common Stock
|
5000
|
$1.02
|
0
|
D
|
|
Stock Option (Right to Buy)
|
$1.33
|
10/29/2013
|
|
D
|
|
|
5000
|
(3)
|
5/13/2020
|
Common Stock
|
5000
|
$1.33
|
0
|
D
|
|
Explanation of Responses:
|
(
1)
|
Shares of common stock which were disposed of in exchange for the right to receive $2.20 per share in cash pursuant to the Agreement and Plan of Merger, dated August 2, 2013 (as it may be amended, the "Merger Agreement"), by and between Juniper Acquisition Corporation (the "Purchaser") and Theragenics Corporation (the "Company") providing for the merger of Purchaser with and into the Company (the "Merger").
|
(
2)
|
The stock options, which provided for vesting in three equal annual installments beginning on 5-14-2010, was cancelled in exchange for the right to receive the difference between the exercise price of the option and $2.20 per share in cash pursuant to the Merger Agreement.
|
(
3)
|
The stock options, which provided for vesting in three equal annual installments beginning on 5-13-2011, was cancelled in exchange for the right to receive the difference between the exercise price of the option and $2.20 per share in cash pursuant to the Merger Agreement.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
DAHLBERG KATHLEEN
96 SOUTH GEORGE STREET
SUITE 500
YORK, PA 17401
|
X
|
|
|
|
Signatures
|
/s/ Lynn Rogers, attorney-in-fact
|
|
10/31/2013
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Theragenics (NYSE:TGX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Theragenics (NYSE:TGX)
Historical Stock Chart
From Aug 2023 to Aug 2024